Clinical Trials Browser

Phase 2 × Unknown × Advanced Non-small-cell Lung Cancer × Clear all

NCT05192681 2022-01-14

Tislelizumab as Cross-line Treatment for Advanced NSCLC

Phase 2 Unknown

Advanced Non-small-cell Lung Cancer